The KDR Gene Hemangioma Capillary Infantile Familial Susceptibility genetic test is a specialized diagnostic tool aimed at identifying genetic predispositions to Infantile Capillary Hemangiomas within families. These benign vascular tumors, most commonly seen in infants, are characterized by their rapid growth phase followed by a slower involution phase. The KDR gene plays a crucial role in the development of these hemangiomas, as mutations in this gene are associated with an increased risk of developing the condition.
This genetic test, conducted at DNA Labs UAE, is a significant advancement in the early detection and management of capillary hemangiomas. By analyzing specific markers in the KDR gene, the test can identify individuals who carry genetic mutations that predispose them to this condition, facilitating early intervention and monitoring for affected infants and their families.
The test is priced at 4400 AED, reflecting the specialized nature of the analysis and the invaluable insights it provides for affected families. By opting for this test, parents and healthcare providers can take proactive steps towards managing and treating infantile capillary hemangiomas, potentially minimizing complications and improving the quality of life for those affected.
The RAD50 gene plays a crucial role in DNA repair mechanisms, particularly in the repair of double-strand breaks. Mutations in this gene have been linked to an increased risk of developing hereditary breast and ovarian cancer syndrome. The RAD50-related genetic test is a specialized diagnostic tool designed to identify mutations in the RAD50 gene. This test is crucial for individuals with a family history of breast or ovarian cancer, as it can help in assessing their risk of developing these conditions.
Performed at DNA Labs UAE, the RAD50 gene test involves analyzing the individual's DNA to detect any abnormalities or mutations in the RAD50 gene that may predispose them to breast or ovarian cancer. The test is recommended for individuals with a strong family history of these cancers or for those who have a known mutation in the RAD50 gene within their family.
The cost of the RAD50 genetic test at DNA Labs UAE is 4400 AED. This investment in health allows individuals to take proactive steps in their cancer prevention strategies, potentially leading to early detection and more effective treatment options. Upon receiving the test results, genetic counseling is advised to understand the implications of the test outcomes and to discuss the next steps in managing the individual's health.
The NDUFA13 gene, also known as GRIM-19, plays a critical role in the proper functioning of the mitochondrial respiratory chain, which is essential for cellular energy production. Mutations in this gene have been linked to various medical conditions, including Hurthle cell thyroid carcinoma (HCTC), a rare and aggressive form of thyroid cancer characterized by the presence of large, eosinophilic cells known as Hurthle cells.
Given the genetic basis of HCTC associated with NDUFA13 mutations, genetic testing can be a valuable tool for early detection, diagnosis, and management of this condition. DNA Labs UAE offers a specialized genetic test designed to identify germline mutations in the NDUFA13 gene, which can predispose individuals to Hurthle cell thyroid carcinoma. This test is crucial for individuals with a family history of thyroid cancer or those who exhibit symptoms associated with HCTC, as it can provide vital information for personalized treatment planning and preventive strategies.
The cost of the NDUFA13 gene genetic test at DNA Labs UAE is 4400 AED. Conducted in a state-of-the-art laboratory by experienced geneticists and clinicians, the test involves a simple blood draw or cheek swab. Results from this test not only aid in the diagnosis of HCTC but also help in assessing the risk for family members, guiding surgical and therapeutic decisions, and improving overall patient outcomes through personalized medicine approaches.
The IDH1 gene, known for its role in cellular metabolism, has gained significant attention in medical research due to its mutation being implicated in various types of cancer, most notably gliomas, a type of brain tumor. The IDH1 Selective Sequencing of Exon 4 Genetic Test is a specialized diagnostic procedure aimed at detecting mutations in exon 4 of the IDH1 gene, which is the most common site for alterations associated with oncogenesis. This precise genetic testing helps in the identification of specific mutations, providing critical information for the diagnosis, prognosis, and treatment planning for patients affected by or at risk of developing cancers associated with IDH1 mutations.
Performed at DNA Labs UAE, a leading facility in genetic diagnostics, the test employs cutting-edge sequencing technologies to accurately analyze the genetic material. With a focus on reliability and accuracy, DNA Labs UAE ensures that the results of the IDH1 Selective Sequencing of Exon 4 Genetic Test are delivered with the highest level of precision, aiding healthcare professionals in making informed decisions about patient care.
The cost of the IDH1 Selective Sequencing of Exon 4 Genetic Test at DNA Labs UAE is 4400 AED. This price reflects the sophisticated nature of the test, including the use of advanced sequencing technologies and the expertise required to interpret the results. For patients and healthcare providers, the investment in this test can be invaluable for its potential to guide personalized treatment strategies and improve patient outcomes in the context of cancers associated with IDH1 mutations.
The "IDH2 Gene IDH2 Selective Sequencing of Exon 4 Genetic Test" is a specialized diagnostic tool available at DNA Labs UAE, designed to analyze the exon 4 region of the IDH2 gene for mutations. The IDH2 gene plays a critical role in cellular metabolism, and mutations within this gene are associated with various types of cancer, including acute myeloid leukemia (AML), gliomas, and chondrosarcomas. The test specifically targets exon 4, a hotspot for pathogenic mutations that can influence disease prognosis and treatment response.
This precise genetic testing technique involves extracting DNA from a patient's sample and selectively sequencing the fourth exon of the IDH2 gene. By doing so, healthcare providers can identify specific mutations that may be present, enabling a more tailored approach to treatment and management of the associated conditions.
The cost of the IDH2 Gene IDH2 Selective Sequencing of Exon 4 Genetic Test at DNA Labs UAE is set at 4400 AED. This investment allows patients and their healthcare teams to gain valuable insights into the genetic underpinnings of their condition, facilitating personalized medicine strategies that can significantly impact patient outcomes.
The "JAK2 Gene JAK2 Selective Sequencing of Exons 12, 14, and 16 Genetic Test" is a specialized diagnostic procedure available at DNA Labs UAE, aimed at identifying mutations within the Janus kinase 2 (JAK2) gene, specifically within exons 12, 14, and 16. The JAK2 gene plays a crucial role in the signaling pathways that regulate blood cell production in the bone marrow. Mutations in this gene are associated with various myeloproliferative disorders, including polycythemia vera, essential thrombocythemia, and myelofibrosis, which are conditions characterized by the excessive production of blood cells.
This test is particularly significant for patients exhibiting symptoms or laboratory findings suggestive of these hematologic disorders, as it helps in confirming the diagnosis, guiding treatment decisions, and assessing prognosis. The sequencing of exons 12, 14, and 16 is critical as mutations in these regions are commonly implicated in the diseases mentioned.
Performed at the state-of-the-art facilities of DNA Labs UAE, the test cost is set at 4400 AED. The price reflects the advanced technology and expertise required to accurately sequence these specific exons of the JAK2 gene. Upon completion, the test provides clinicians with vital genetic information, enabling personalized patient management strategies based on the genetic makeup of the individual's condition.
CBL Gene Juvenile Myelomonocytic Leukemia (JMML) due to CBL Germline Mutation Genetic Test is a specialized diagnostic procedure available at DNA Labs UAE, designed to detect mutations in the CBL gene, which are implicated in the development of JMML. This rare, yet aggressive form of leukemia primarily affects young children and is characterized by the overproduction of myelomonocytes, a type of white blood cell. The test is crucial for confirming a diagnosis of JMML caused by CBL mutations, enabling targeted treatment strategies and genetic counseling for affected families. The cost of the test is set at 4400 AED, reflecting the advanced genetic analysis involved in identifying the specific mutations within the CBL gene. By opting for this test, healthcare providers and families can gain valuable insights into the genetic underpinnings of the disease, facilitating more informed decisions regarding patient care and management.
The BMPR1A Gene Juvenile Polyposis Syndrome Genetic Test is a specialized diagnostic tool designed to identify mutations in the BMPR1A gene, which are linked to Juvenile Polyposis Syndrome (JPS). JPS is a hereditary condition characterized by the development of numerous polyps in the gastrointestinal tract during childhood or adolescence, which can potentially lead to cancer if left unchecked. The test involves analyzing the patient's DNA to detect any genetic abnormalities in the BMPR1A gene that may indicate a predisposition to JPS.
Performed at DNA Labs UAE, a leading facility in genetic testing, this test offers a crucial insight for individuals with a family history of JPS or those exhibiting symptoms related to the condition. By identifying mutations early, it enables proactive management and surveillance of the syndrome, significantly reducing the risk of developing gastrointestinal cancers. The cost of the BMPR1A Gene Juvenile Polyposis Syndrome Genetic Test is 4400 AED, reflecting the sophisticated technology and expertise required to accurately identify mutations in the BMPR1A gene. This test is an invaluable resource for at-risk individuals and their families, offering a pathway to informed decision-making regarding their health and preventive care.
The SMAD4 Gene Juvenile Polyposis Syndrome Genetic Test is a specialized diagnostic procedure designed to identify mutations in the SMAD4 gene, which are linked to Juvenile Polyposis Syndrome (JPS). JPS is a rare genetic condition characterized by the growth of numerous polyps in the gastrointestinal tract during childhood or adolescence, which can potentially lead to colorectal cancer if left undetected or untreated. The SMAD4 gene plays a crucial role in cellular signaling and the regulation of cell growth, and mutations in this gene are a known cause of JPS.
Conducted at DNA Labs UAE, a leading facility in genetic testing, this test provides a comprehensive analysis of the SMAD4 gene to detect any abnormalities that may indicate a predisposition to JPS. It is particularly recommended for individuals with a family history of JPS or those who have symptoms associated with the syndrome, such as gastrointestinal bleeding, anemia, or abdominal pain.
The cost of the SMAD4 Gene Juvenile Polyposis Syndrome Genetic Test at DNA Labs UAE is 4400 AED. The test involves a simple blood draw or cheek swab, and results are typically available within a few weeks. The results can provide valuable information for the early detection and management of JPS, including surveillance and preventive measures, thereby significantly reducing the risk of developing colorectal cancer associated with the syndrome.
The SMAD4 Gene Juvenile Polyposis/Hereditary Hemorrhagic Telangiectasia Syndrome Genetic Test is a sophisticated diagnostic tool offered by DNA Labs UAE, aimed at identifying mutations in the SMAD4 gene. These mutations are associated with two distinct but sometimes overlapping conditions: Juvenile Polyposis Syndrome (JPS) and Hereditary Hemorrhagic Telangiectasia (HHT) syndrome. JPS is characterized by the development of numerous polyps in the gastrointestinal tract during childhood or adolescence, which can lead to an increased risk of gastrointestinal cancer. HHT, on the other hand, is known for causing blood vessels to form incorrectly, leading to bleeding, anemia, and sometimes more severe complications like organ arteriovenous malformations.
The genetic test, priced at 4400 AED, involves analyzing the patient's DNA to check for specific mutations in the SMAD4 gene that are known to contribute to these conditions. By identifying these mutations, the test can help in confirming a diagnosis, allowing for early intervention, and providing crucial information for family planning. It is particularly valuable for individuals with a family history of either condition, as it can identify at-risk family members, enabling proactive health management and surveillance for potential complications associated with these syndromes. Conducted at DNA Labs UAE, this test represents a critical step forward in the personalized management and understanding of these complex hereditary conditions.
